Concepedia

Author

K. R. Bogaard

The University of Texas MD Anderson Cancer Center

Also Known As

K. Bogaard, K. R. Bogaard, Karla Bogaard, Karla R. Bogaard

8

Publications

166

Citations

5

H-Index

13

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center
KR

About

K. R. Bogaard is an author at The University of Texas MD Anderson Cancer Center specializing in cancer research, clinical trials, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Health Sciences

1

1

22

2

Medicine

1

1

22

3

Pharmacology

1

1

22

4

Cancer Therapeutics

1

1

22

5

Clinical Trials

1

1

22

K. R. Bogaard

×

4

Publications

153

Citations

4

H-Index

YearCitations

Phase I study to determine the safety and pharmacokinetics of oral administration of TAS‐102 in patients with solid tumors

David S. Hong, James L. Abbruzzese, K. R. Bogaard,

Cancer

2006

86

A Phase I Study of Escalating Doses of the Tyrosine Kinase Inhibitor Semaxanib (SU5416) in Combination with Irinotecan in Patients with Advanced Colorectal Carcinoma

Paulo M. Hoff, Robert A. Wolff, K. R. Bogaard,

Japanese Journal of Clinical Oncology

2006

35

Preliminary results from a phase II study of infusional 5-FU, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer (mCRC)

Scott Kopetz, James L. Abbruzzese, Cathy Eng,

Journal of Clinical Oncology

2006

22

Phase II trial of combined irinotecan and oxaliplatin given every 3 weeks to patients with metastatic colorectal cancer

Paulo M. Hoff, Robert A. Wolff, Henry Xiong,

Cancer

2006

10

Page 1